◆ Market Data --:--
⛽ Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

BriaCell Therapeutics Corp.

BCT.TO TSX Healthcare Biotechnology West Vancouver, Canada
Loading stock data...
Stock Performance
Price History
- Drag to select time range -
Market Data
Market Cap 40.2M
P/E Ratio -
52-Week High -
52-Week Low -
Avg Volume -
Beta -
Forward P/E -
Dividend Yield -
EV/Revenue -
Price/Book -
Business Overview

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Healthcare Biotechnology TSX
Key Financial Metrics
-
Revenue
-4.8M
Net Income
C$-43.68
EPS (Diluted)
-24.6M
Free Cash Flow
Profitability
Gross Margin -
Operating Margin -
Net Profit Margin -
EBITDA -4.8M
Returns & Efficiency
Return on Assets (ROA) -81.6%
Return on Equity (ROE) -
Dividend Yield -
Payout Ratio -
Financial Health
Total Assets 5.9M
Total Debt -
Debt to Equity -
Current Ratio 0.49
Company Info
IndustryBiotechnology
HQWest Vancouver, Canada
Fiscal Year End1753920000
CurrencyCAD
Websitebriacell.com
Peers
7.9B
P/E: --
2.5B
P/E: 12.0
2.5B
P/E: 23.7
2.2B
P/E: 53.2
1.4B
P/E: 24.1
1.2B
P/E: --
1.1B
P/E: --
631.8M
P/E: --
Insider Activity
Sentiment Bullish
Shares Bought 1,386,003
Shares Sold 0
Total Transactions 12
SEDAR+ Filings
View All Filings
19
Annual Reports
15
Quarterly Reports
24
MD&A
120
News Releases
6
Material Changes
9
Governance
52
Certifications
45
Other

● Interim financial statements/report – English.pdf
2025-12-11
● Interim financial statements/report – English.pdf
2024-12-16
● Interim financial statements/report – English.pdf
2023-12-14
● Interim financial statements/report – English.pdf
2022-12-14
● Interim financial statements/report (amended) - English.pdf
2022-10-27
View all 15 quarterly reports →

● Interim MD&A - English.pdf
2025-12-11
● Annual MD&A - English.pdf
2025-10-15
● Interim MD&A - English.pdf
2024-12-16
● Interim MD&A - English.pdf
2023-12-14
● Annual MD&A - English.pdf
2023-10-25
View all 24 md&a →

● News release - English.pdf
2026-02-18
● News release - English.pdf
2026-02-17
● News release - English.pdf
2026-01-28
● News release - English.pdf
2026-01-27
● News release - English.pdf
2026-01-15
View all 120 news releases →

● Material change report - English.pdf
2025-08-27
● Material change report - English.pdf
2023-09-11
● Material change report - English.pdf
2020-12-01
● Material change report - English.pdf
2020-11-20
● Material change report - English.pdf
2020-08-19
View all 6 material changes →

● Management information circular - English.pdf
2026-02-12
● Form of proxy - English.pdf
2026-02-12
● Management information circular - English.pdf
2024-12-17
● Form of proxy - English.pdf
2024-12-17
● Management information circular (amended) - English.pdf
2019-10-08
View all 9 governance →

● 52-109F2 - Certification of interim filings - CFO (E).pdf
2025-12-11
● 52-109F2 - Certification of interim filings - CEO (E).pdf
2025-12-11
● 52-109F1 - Certification of annual filings - CEO (E).pdf
2025-10-15
● 52-109F1 - Certification of annual filings - CFO (E).pdf
2025-10-15
● 52-109F2 - Certification of interim filings - CEO (E).pdf
2024-12-16
View all 52 certifications →

● Notice of meeting - English.pdf
2026-02-12
● Other.pdf
2026-02-12
● Other.pdf
2026-02-12
● Other.pdf
2026-02-12
● Notice of the meeting and record date (amended) - English.pdf
2026-01-19
View all 45 other →
Interactive Charts
Full Chart View
Company Profile
General Information
Company NameBriaCell Therapeutics Corp.
TickerBCT.TO
ExchangeTSX
SectorHealthcare
IndustryBiotechnology
HeadquartersWest Vancouver, Canada
Fiscal Year End1753920000
CurrencyCAD
Websitebriacell.com
Financial Summary
Market Cap40.2M
RevenueN/A
Net Income-4.8M
P/E RatioN/A
EPS (Diluted)C$-43.68
Net MarginN/A
ROEN/A
Dividend YieldN/A
Business Description
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
NEWS
Loading news...
TRENDING
Loading...